What is Molnupiravir

Molnupiravir
It is an oral capsule developed by the American pharmaceutical company Merck (MSD). The results of the third phase of clinical trials in 2021 show that it can reduce the risk of hospitalization or death from Covid-19 by about 30%.

National license
In addition to obtaining the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) at the end of 2021, Molnupiravir has also obtained conditional marketing authorization in the UK. Emergency use before permission.
Taiwan also passed the EUA on January 13, 2022.
On February 17, 2022, the Drug Administration of the Ministry of Health of Vietnam issued an emergency authorization to designate Vietnamese companies to produce 3 kinds of Molnupiravir component drugs.

Objects of use <br>Each course of treatment is 5 days, take 2 capsules of 400mg every 12 hours, a total of 20 capsules

Contraindications <br>For F0 (diagnosed) use only, not authorized for use in the prevention of Covid-19.
Minors should not use it, as it may affect the growth of bones and cartilage.
Pregnant women should not use it, it may cause harm to the fetus.
If pregnancy is planned, adult men and women are advised to use contraception within three months after treatment.

Side Effects <br>Due to the limited clinical experience of Molnupiravir, all possible risks have not been fully confirmed yet,
Diarrhea, nausea, dizziness, etc. may occur, and serious and unexpected side effects may also occur.

Conclusion <br>Currently Molnupiravir is only available for F0 (diagnosed patients). For preventive use and for minors, pregnant women, and pregnancy-preparing groups, other prescriptions are still required, and more clinical information is still needed to complete the drug efficacy and side effects.

source